neoplastic meningitis


Also found in: Wikipedia.

ne·o·plas·tic men·in·gi·tis

infiltration of subarachnoid space by neoplastic cells, typically medulloblastoma or metastatic carcinoma.
Mentioned in ?
References in periodicals archive ?
Their topics include the pathology and molecular genetics of common brain tumors, malignant gliomas in adults, low grade astrocytomas, pediatric neuro-oncology, the managing intramedullary spinal cord tumors, medical complications in the management of brain tumor, brain metastases, neoplastic meningitis, the neurotoxicity of chemotherapy, paraneoplastic disorders, and neurological complications of bone marrow and organ transplantation.
Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain.
Acromegaly lanreotide acetate octreotide acetate Hormone Therapy Medroxyprogesterone Somatropin Infectious Disease Interferon Metabolic Exenatide Oncology Neoplastic Meningitis Cytarabine Prostate leuprolide acetate leuprolide acetate triptorelin pamoate Schizophrenia Fluphenazine Haloperidol paliperidone palmitate olanzapine risperidone Substance Abuse naltrexone Reproductive Health Estradiol valerate Depo-estradiol Depo-testosterone
The full approval was based on findings from two randomized controlled clinical trials that included over 200 patients with neoplastic meningitis related to solid tumors, lymphoma or leukemia.
Approximately 25,000 cases of neoplastic meningitis occur annually, of which approximately 40 percent are lymphomatous meningitis and 60 percent are neoplastic meningitis in patients with solid tumors.
LONDON, May 31 /PRNewswire-FirstCall/ -- SkyePharma PLC ( LSE: SKP) announces today that at the forthcoming 2006 Annual Meeting of the American Society of Clinical Oncology ("ASCO"), which is being held in Atlanta, Georgia on June 2-6, two papers will be presented on DepoCyt(R), SkyePharma's treatment for neoplastic meningitis.
Neoplastic meningitis occurs when metastases from lymphomas, solid tumors, or leukemia spread to the tissue surrounding the brain and spinal cord.
SkyePharma is currently conducting a Phase IV study, the data from which will be submitted in applications to the FDA and EMEA to expand the treatment indication for DepoCyt(R)/DepoCyte(R) to neoplastic meningitis associated with solid tumours.
Lymphomatous meningitis is a subtype of neoplastic meningitis (NM).
Food and Drug Administration (FDA) has advised the company that it is currently scheduling its New Drug Application (NDA) for DepoCyt(TM) for the treatment of neoplastic meningitis (NM) from lymphomas for review by the FDA's Oncologic Drugs Advisory Committee (the "Committee") on Nov.
Earlier this year, data from a Phase I clinical study of Partaject- delivered busulfan suggested the drug is safe and effective in patients with neoplastic meningitis, an end-stage condition where 5 to 30 percent of all solid tumors metastasize to the meninges area of the brain.
Food and Drug Administration (FDA) inviting the company to submit a New Drug Application (NDA) for DepoCyt(tm), an anti-cancer drug for the treatment of neoplastic meningitis (NM) from lymphomas.